The concept of using mRNA to produce its own medicine in situ in the body makes it an ideal
drug candidate, holding great potential to revolutionize the way we approach medicine. The …

Lipid nanoparticles (LNPs) can be designed to potentiate cancer immunotherapy by
promoting their uptake by antigen-presenting cells, stimulating the maturation of these cells …

Lipid nanoparticles hold great potential as an effective non-viral vector for nucleic acid-
based gene therapy. Plasmid DNA delivery can result in extended transgene expression …

Gene therapy is designed to cure various diseases resulting from genetic defects. Currently,
recombinant adeno-associated viral vectors (rAAV) are the vehicles of choice for therapeutic …

Combined treatment of immunotherapy and radiotherapy shows promising therapeutic
effects for the regression of a variety of cancers. However, even multi‐modality therapies …

Size-dependent phagocytosis is a well-characterized phenomenon in monocytes and
macrophages. However, this size effect for preferential gene delivery to these important cell …

Recombinant adeno‐associated virus (rAAV) vectors are a promising platform for in vivo
gene therapies. However, cost‐effective, well‐characterized processes necessary to …

Recombinant adeno‐associated viral vectors (rAAVs) are one of the most used vehicles for
gene therapy, with five rAAV therapeutics commercially approved by the FDA. To improve …

Gene therapies and cellular programming rely on effective cell transfection. Despite
continuous advancements in carrier development and transfection techniques to enhance …

The use of lentiviral vectors (LV) in gene therapy has been growing in recent years. To meet
the increasing clinical demand, LV production platforms will benefit from improved …